Samuel Z. Goldhaber, MD, principal investigator of ADOPT, spoke with Cardiovascular Business about the findings of his 2011 AHA late-breaking clinical trial. Image Source: North American Thrombosis Forum

ORLANDO, Fla.—Samuel Z. Goldhaber, MD, principal investigator of ADOPT, discussed the design and negative findings of the trial, which compared an extended course of thromboprophylaxis with apixaban (Eliquis, Bristol-Myers Squibb) with enoxaparin (Lovenox, Sanofi-Aventis) for medically ill patients with venous thromboembolism with Cardiovascular Business.

While the findings from ADOPT were negative, mainly due to the underpowered nature of the trial, Goldhaber recommended a new trial design that could potentially produce stronger results from a properly powered trial. This trial was presented Nov. 13 as a late-breaking clinical trial at the American Heart Association (AHA) scientific sessions.

This video was conducted collaboratively with ClinicalTrialResults.org.